These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 15974994)

  • 1. Congestive heart failure: pharmacological agents and the potential of B-type natriuretic Peptide.
    James KD; Cataliotti A; Schirger JA; Plonka S; Burnett JC
    Curr Med Chem; 2005; 12(12):1439-47. PubMed ID: 15974994
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Trends in pharmacological treatment of congestive heart failure].
    Halawa B
    Pol Merkur Lekarski; 1999 Mar; 6(33):152-6. PubMed ID: 10365602
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contemporary medical management of left ventricular dysfunction and congestive heart failure.
    Teo KK; Ignaszewski AP; Gutierrez R; Hill KL; Martin SL; Calhoun HP; Humen DP; Montague TJ
    Can J Cardiol; 1992; 8(6):611-9. PubMed ID: 1354569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Assessing the treatment of congestive heart failure: inotropic agents and calcium channel blockers.
    Hilleman DE
    Pharmacotherapy; 1993; 13(5 Pt 2):88S-93S. PubMed ID: 7901842
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacoeconomic considerations in assessing and selecting congestive heart failure therapies.
    Levy E; Levy P
    Pharmacoeconomics; 2002; 20(14):963-77. PubMed ID: 12403637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study.
    Cheng V; Kazanagra R; Garcia A; Lenert L; Krishnaswamy P; Gardetto N; Clopton P; Maisel A
    J Am Coll Cardiol; 2001 Feb; 37(2):386-91. PubMed ID: 11216951
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Newer drug therapy for congestive heart failure.
    Coodley E
    Arch Intern Med; 1999 Jun; 159(11):1177-83. PubMed ID: 10371225
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epidemiological and pharmacological profile of congestive heart failure at Turkish academic hospitals.
    Ergin A; Eryol NK; Unal S; Deliceo A; Topsakal R; Seyfeli E
    Anadolu Kardiyol Derg; 2004 Mar; 4(1):32-8. PubMed ID: 15033616
    [TBL] [Abstract][Full Text] [Related]  

  • 9. BNP-guided vs symptom-guided heart failure therapy: the Trial of Intensified vs Standard Medical Therapy in Elderly Patients With Congestive Heart Failure (TIME-CHF) randomized trial.
    Pfisterer M; Buser P; Rickli H; Gutmann M; Erne P; Rickenbacher P; Vuillomenet A; Jeker U; Dubach P; Beer H; Yoon SI; Suter T; Osterhues HH; Schieber MM; Hilti P; Schindler R; Brunner-La Rocca HP;
    JAMA; 2009 Jan; 301(4):383-92. PubMed ID: 19176440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance.
    Abassi Z; Karram T; Ellaham S; Winaver J; Hoffman A
    Pharmacol Ther; 2004 Jun; 102(3):223-41. PubMed ID: 15246247
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current concepts in clinical therapeutics: congestive heart failure.
    Klamerus KJ
    Clin Pharm; 1986 Jun; 5(6):481-98. PubMed ID: 2872992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Maximizing the natriuretic peptide system in experimental heart failure: subcutaneous brain natriuretic peptide and acute vasopeptidase inhibition.
    Chen HH; Lainchbury JG; Harty GJ; Burnett JC
    Circulation; 2002 Feb; 105(8):999-1003. PubMed ID: 11864932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure.
    Yoshimura M; Yasue H; Tanaka H; Kikuta K; Sumida H; Kato H; Jougasaki M; Nakao K
    Br Heart J; 1994 Dec; 72(6):528-33. PubMed ID: 7857734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Current and novel pharmacological approaches to renal insufficiency in heart failure.
    Hindnavis V; Tang WH
    Minerva Cardioangiol; 2006 Dec; 54(6):753-62. PubMed ID: 17167387
    [TBL] [Abstract][Full Text] [Related]  

  • 15. What to try while congestive heart failure patients are still ambulatory.
    Jennison SH; Miller LW
    Postgrad Med; 1993 Oct; 94(5):66-8, 71, 75-8 passim. PubMed ID: 8415337
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Temporal trends in pharmacological therapy in the IN-CHF registry from 1995 to 2005].
    Fabbri G; Gorini M; Maggioni AP; Di Lenarda A;
    G Ital Cardiol (Rome); 2007 Feb; 8(2):102-6. PubMed ID: 17402354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. From digoxin to angiotensin-converting enzyme inhibitors: issues in pharmacotherapy for congestive heart failure.
    Hackenbruck HA
    Clin Excell Nurse Pract; 2000 Jul; 4(4):197-204. PubMed ID: 11261079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update in the approach to and management of heart failure.
    Gelow JM; Fang JC
    South Med J; 2006 Dec; 99(12):1346-55; quiz 1356-7, 1384. PubMed ID: 17233191
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Brain natriuretic peptide enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in experimental heart failure.
    Cataliotti A; Boerrigter G; Costello-Boerrigter LC; Schirger JA; Tsuruda T; Heublein DM; Chen HH; Malatino LS; Burnett JC
    Circulation; 2004 Apr; 109(13):1680-5. PubMed ID: 15023890
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Drug therapy of heart failure].
    Follath F
    Ther Umsch; 1993 Jun; 50(6):425-33. PubMed ID: 8351674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.